

Diego Chowell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10739446/publications.pdf>

Version: 2024-02-01

28
papers

5,795
citations

361413

20
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

10528
citing authors

#	ARTICLE	IF	CITATIONS
1	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	28.4	1,657
2	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	28.9	1,515
3	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	12.6	834
4	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019, 25, 767-775.	30.7	282
5	TCR contact residue hydrophobicity is a hallmark of immunogenic CD8 ⁺ T cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1754-62.	7.1	200
6	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 1715-1720.	30.7	194
7	Single-cell sequencing links multiregional immune landscapes and tissue-resident T _H 1 cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	16.8	179
8	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1386-1392.	6.3	137
9	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	28.9	131
10	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	17.5	110
11	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 2859-2870.	7.0	75
12	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
13	HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. <i>Clinical Cancer Research</i> , 2015, 21, 2861-2869.	7.0	59
14	HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. <i>Oral Oncology</i> , 2015, 51, 662-667.	1.5	51
15	Modelling the effect of early detection of Ebola. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 148-149.	9.1	46
16	Genetic and environmental determinants of human TCR repertoire diversity. <i>Immunity and Ageing</i> , 2020, 17, 26.	4.2	42
17	Modeling the Subclonal Evolution of Cancer Cell Populations. <i>Cancer Research</i> , 2018, 78, 830-839.	0.9	37
18	Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study. <i>Oral Oncology</i> , 2015, 51, 751-758.	1.5	34

#	ARTICLE	IF	CITATIONS
19	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. <i>Nature Genetics</i> , 2022, 54, 996-1012.	21.4	30
20	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	3.1	28
21	Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade. <i>JAMA Network Open</i> , 2022, 5, e220448.	5.9	26
22	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	3.4	20
23	Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade. <i>Npj Precision Oncology</i> , 2022, 6, 23.	5.4	17
24	Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. <i>Cancer</i> , 2017, 123, 4886-4894.	4.1	16
25	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	9.4	7
26	Modeling the Case of Early Detection of Ebola Virus Disease. , 2016, , 57-70.		2
27	When (distant) relatives stay too long: implications for cancer medicine. <i>Genome Biology</i> , 2016, 17, 34.	8.8	2
28	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 2-3.	1.4	0